VEGFA and metastatic neoplasm: For metastatic disease sunitinib and sorafenib (VEGF inhibitors) have now been licensed in the United Kingdom on the basis of evidence from large randomised controlled clinical trials (Motzer et al, 2007; Escudier et al, 2007).